The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...
The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.
The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to undergo massive ...
Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s ...
The resolution could potentially restrict how telehealth programs offer cheaper versions known as compounded drugs ...
The FDA determined that Novo Nordisk’s obesity and diabetes drugs were no longer in short supply. Elsewhere, Concentra made a ...
A small but significant new study showed low doses of Ozempic helped people to drink less. Scientists are starting to ...
Then, the Ozempic boom happened. Celebrities like Khloé Kardashian and Oprah Winfrey were sharing their experience with ...